Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ME2 | P23368 | 1/20 | 0.32 |
| ▸ | ME1 | P48163 | 1/20 | 0.32 |
| ▸ | ME3 | Q16798 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689189 | 0.76 | PPARA (0.49) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL2686642 | 0.72 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL5689292 | 0.68 | PPARA (0.63) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3946198 | 0.68 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3100628 | 0.68 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL13156113 | 0.68 | PPARA (0.60) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL6094837 | 0.68 | PPARA (0.49) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3100619 | 0.68 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL6092849 | 0.68 | PPARA (0.49) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3115799 | 0.67 | PPARA (0.47) | PPARAPPARGPPARDLMNAME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638929-A1 | PROCESS FOR THE PREPARATION OF RACEMIC 2- ¬2-(4-HYDROXYPHENYL)ETHYL|-THIO -3-¬4-(2- 4-¬(METHYLSULFONYL)OXY|PHENOXY ETHYL)PHENYL|PROPANOIC ACID. | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113285-A1 | PROCESS FOR THE PREPARATION OF RACEMIC 2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20080090905-A1 | Amine Salts Of (-)-2-((2-(4-Hydroxyphenyl)Ethyl)Thio)-3-(4-(2-(4-((Methylsulfonyl)Oxy)Phenoxy)Ethyl)Phenyl) Propanoic Acid | SNAPE EVAN W | 2008-04-17 | — | — | US | disclosed |
| EP-1638930-A1 | AMINE SALTS OF (-)-2- ¬2-(4-HYDROXYPHENYL)ETHYL|-THIO -3-¬4-(2- 4-¬(METHYLSULFONYL)OXY|PHENOXY ETHYL)PHENYL|PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113283-A1 | AMINE SALTS OF (-)-2-{`2-(4-HYDROXYPHENYL) ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY! PHENOXY}ETHYL)PHENYL! PROPANOIC ACID AND THERE USE IN MEDICINE | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090905-A1 | Amine Salts Of (-)-2-((2-(4-Hydroxyphenyl)Ethyl)Thio)-3-(4-(2-(4-((Methylsulfonyl)Oxy)Phenoxy)Ethyl)Phenyl) Propanoic Acid | GPR119, CPT1B, PNLIP | PPARA 75/4885PPARG 554/4885PPARD 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.